Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Pancreatic neuroendocrine tumors although rare , have been significantly increased over the past few decades. They range from indolent to highly aggressive in nature. Just like breast and endometrial carcinoma are hormonal dependant,
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Fatima A
Keywords: high positive ERβ, Hormonal therapy, small size PanNET,
Introduction: Primary neuroendocrine carcinoma of the breast is an extremely rare tumor with incidence of 0.27-0.5%.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author:
Authors: Macut D, Kecman G, Bogavac T, Popovic B, Bozic I,
Keywords: neuroendocrine carcinoma, breast carcinoma, hormonal therapy,
Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author: Kassem S
Authors: Kassem S, Gross D, Doviner V, Dresner-Pollak R,
Keywords: pituitary carcinoma, peptide receptor radionuclide therapy, acromegaly,